Dose Escalation of POL6326 in Combination With Eribulin in Patients With Metastatic Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01837095
Recruitment Status : Active, not recruiting
First Posted : April 22, 2013
Last Update Posted : February 1, 2017
Information provided by (Responsible Party):
Polyphor Ltd.

No Study Results Posted on for this Study
  Recruitment Status : Active, not recruiting
  Estimated Primary Completion Date : April 2017
  Estimated Study Completion Date : June 2017